Skip to main content
Log in

Immunotherapy with tumor cell subpopulations

II. Therapy of drug-resistant L1210 leukemia and EL4 lymphoma

  • Original Articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

Tumor cell subpopulations were isolated from parental (drug-sensitive) L1210 tumor by lectinnylon chromatography and evaluated in active, specific immunotherapy of a thioguanine-resistant L1210 subline. Cells released by mannoside were effective in causing regression of the variant subline. This effectiveness was not altered by treatment of the subpopulation with neuraminidase. Subpopulations either not binding fucose-specific columns or released from glucose-specific columns were also effective immunogens. Studies using the syngeneic EL4 lymphoma model indicated that mannoside-released cells were effective in combination chemotherapy-immunotherapy. The results further demonstrate the feasibility of this approach to active, specific immunotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Cantrell, J. L., Killion, G. M., Kollmorgen, G. M.: Correlations between humoral immunity and successful chemotherapa-immunotherapy. Cancer Res. 36, 3051–3057 (1976)

    Google Scholar 

  • Fidler, I. J., Kripke, M. L.: Metastasis results from preexisting variant cells within a malignant tumor. Science 197, 893–895 (1977)

    Google Scholar 

  • Fridberg, S.: Comparison of an immunoresistant and an immunosusceptible ascites subline from the murine tumor TA3. I. Transplantability, morphology, and some physicochemical characteristics. J. Natl. Cancer Inst. 48, 1463–1476 (1972)

    Google Scholar 

  • Gutterman, J. U.: Cancer systemic active immunotherapy today — Prospects for tomorrow. Cancer Immunol. Immunother. 2, 1–9 (1977)

    Google Scholar 

  • Hersh, E. M., Gutterman, J. U., Mavlight, G.: Immunotherapy of cancer in Man. Springfield, Ill.: Charles C. Thomas 1973

    Google Scholar 

  • Hosokawa, M., Irsini, F., Mihich, E.: Fast- and slow-growing tumors derived from spontaneous mammary tumors of the DBA/2 Ha-DD mouse. Cancer Res. 35, 2657–2662 (1975)

    Google Scholar 

  • Hyman, R., Stallings, V.: Complementation patterns of Thy-1 variants and evidence that antigen loss variants pre-exist in the parental population. J. Natl. Cancer Inst. 52, 492–436 (1974)

    Google Scholar 

  • Ishidate, M., Jr., Aoshima, M., Sakurai, Y.: Population changes of a rat leukemia by different routes of transplantation. J. Natl. Cancer Inst. 53, 773–781 (1974)

    Google Scholar 

  • Jacobs, D. M., Kripke, M. L.: Accelerated development of transplanted mammary tumors in mice pretreated with the methanol extraction residue of BCG and prevention of acceleration by concomitant specific immunization. J. Natl. Cancer Inst. 2, 219–224 (1974)

    Google Scholar 

  • Kessel, D., Bosmann, H. B.: On the characteristics of actinomycin D resistance in L5178Y cells. Cancer Res. 30, 2695–2699 (1970)

    Google Scholar 

  • Killion, J. J.: The immunotherapeutic value of a L1210 tumor cell vaccine depends upon the expression of cell-surface carbohydrates. Cancer Immunol. Immunother. 3, 87–91 (1977)

    Google Scholar 

  • Killion, J. J.: Immunotherapy with tumor cell subpopulations. I. Active, specific immunotherapy of L1210 leukemia. Cancer Immunol. Immunother. 4, 115–119 (1978)

    Google Scholar 

  • Killion, J. J., Kollmorgen, G. M.: Isolation of immunogenic tumor cells by cell-affinity chromatography. Nature 259, 674–676 (1976)

    CAS  PubMed  Google Scholar 

  • Killion, J. J., Wallenbrock, M. A., Rogers, J. A., Kollmorgen, G. M., Sansing, W. A., Cantrell, J. L.: Tumorigenicity and the expression of cell-surface carbohydrates. Nature 261, 54–56 (1976)

    CAS  PubMed  Google Scholar 

  • Killion, J. J., Wallenbrock, M. A., Kollmorgen, G. M., Sansing, W. A.: Properties of tumor cell vaccines. Cancer Res. 18, 54a (1977)

  • LeFever, A. V., Killion, J. J., Kollmorgen, G. M., Cantrell, J. L.: Immunotherapeutic value of neuraminidase-treated, drug-resistant tumor cells. In Vitro 10, 388a (1974)

  • LeFever, A. V., Killion, J. J., Kollmorgen, G. M.: Active immunotherapy of L1210 leukemia with neuraminidase-treated, drug-resistant L1210 sublines. Cancer Immunol. Immunother. 1, 211–217 (1976)

    Google Scholar 

  • Mihich, E., Kitano, M.: Differences in the immunogenicity of leukemia L1210 sublines in DBA/2 mice. Cancer Res. 31, 1999–2010 (1971)

    Google Scholar 

  • Nicolin, A., Vadlamudi, S., Goldin, A.: Antigenicity of L1210 leukemic sublines induced by drugs. Cancer Res. 32, 653–660 (1972)

    Google Scholar 

  • Sedlacek, H. H., Meesmann, H., Seiler, F. R.: Regression of spontaneous mammary tumors in dogs after injection of neuraminidase-treated tumor cells. Int. J. Cancer 15, 409–416 (1975)

    Google Scholar 

  • Wallenbrock, M. A., Killion, J. J.: Isolation of high-rate DNA synthetic cells by con A chromatography. J. Cell. Physiol. 95, 151–158 (1978)

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Killion, J.J. Immunotherapy with tumor cell subpopulations. Cancer Immunol Immunother 5, 21–26 (1978). https://doi.org/10.1007/BF00199203

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00199203

Keywords

Navigation